In my previous article, we explored how CRISPR-Cas9 enables precise gene editing, but its potential goes far beyond simply correcting mutations. What if the solution to the global organ shortage did not come from donors at all, but from an entirely different species?
Sounds ambitious, right? This is exactly where xenotransplantation comes in.
Xenotransplantation refers to the transplantation of organs between different species, most commonly from pigs to humans. However, this approach has long been limited by the human immune system. Pig cells express carbohydrate antigens such as the α-Gal epitope, which are immediately recognised by human antibodies and trigger hyperacute rejection, a rapid immune response that can destroy the organ within minutes.
This is where CRISPR becomes a game changer.
Using CRISPR-Cas9, scientists can knock out key genes such as GGTA1, which is responsible for producing the α-Gal antigen. Additional genes like CMAH and β4GALNT2 are also removed to further reduce immune recognition. Importantly, CRISPR allows multiple genes to be edited at once, which is crucial because immune rejection involves several pathways.
Beyond removing antigens, CRISPR is also used to insert human genes into pig DNA. For example, complement regulatory proteins such as CD46 and CD55 help reduce immune activation, while genes like thrombomodulin improve blood clot regulation, both of which increase the chances of transplant success.
Another major concern is safety. Pig genomes contain porcine endogenous retroviruses, or PERVs, which could potentially infect human cells. Using CRISPR, researchers have successfully inactivated these viral sequences, significantly improving biosafety.
Recent experimental pig to human transplants, including early heart and kidney procedures using extensively gene edited organs, have shown that such organs can function in the human body, marking a significant step toward real clinical application, even though long term success is still being studied.
However, challenges remain. While hyperacute rejection has been reduced, longer term immune responses are not yet fully controlled. There are also concerns about off target effects of CRISPR, as well as ethical issues surrounding the use of genetically modified animals.
Despite this, xenotransplantation highlights the true potential of CRISPR, moving beyond gene editing toward solving real world medical challenges. If successful, it may not just solve the organ shortage but completely redefine what is medically possible.
